Mechanisms of resistance to immune checkpoint inhibitors in renal cell carcinoma and novel treatment strategies
- 1Department of Pharmacy, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University
- 2Department of Urology, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University
Abstract
In recent years, immune checkpoint inhibitors (ICIs), such as nivolumab, ipilimumab, pembrolizumab, and atezolizumab have substantially improved the prognosis of patients with advanced renal cell carcinoma. These agents have greatly changed the management of advanced renal cell carcinoma, shifting the treatment paradigm from cytokine and vascular endothelial growth factor-based therapies to immunotherapy strategies. However, drug resistance limits the long-term benefit. The mechanisms of immunotherapy resistance in RCC are complex. Recently, increasing research has focused on how cancer cells evade the surveillance and attack of the immune system and identifying the molecular and cellular drivers of resistance. In response, combination regimens incorporating ICIs are being developed to alleviate drug resistance and attack cancer cells through multiple pathways. At the same time, novel targeted strategies are under investigation to develop innovative approaches to delay, partially overcome, or bypass resistance in defined clinical settings. This review outlines the mechanisms of immunotherapy resistance in RCC from three interrelated perspectives: cancer cell-intrinsic mechanisms, the tumor microenvironment, and host related factors. We also summarize current efforts to overcome resistance, including ICI combined with tyrosine kinase inhibitors, dual ICI therapy, tumor microenvironment-targeting strategies, radiotherapy combined with immunotherapy, and gut microbiota modulation. Although these new strategies have shown different therapeutic effects in clinical trials, deeper understanding of immune regulation highlights their potential. Moreover, the integration of multi-omics analysis, and microbiome regulation may increase patient choices and optimize therapeutic outcomes, but their clinical efficacy has not been fully confirmed and requires prospective, treatment defined validation. Overall, ICIs have substantially changed RCC treatment, future progress will depend on deeper biological insights, rational combination design, and validated personalized immunotherapy.
Related
- Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
- Mechanisms of Resistance and Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Narrative Review.
- Overcoming the Shield: Mechanisms of Resistance to DNA Repair Inhibitors and Strategies to Restore Synthetic Lethality
- Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma : A case report
- Integration of Immune checkpoint inhibitors within the definitive radiotherapy-based treatment continuum for locally advanced mucosal head and neck squamous cell carcinoma: a scoping review protocol
BibTeX
@article{chen2026mechanisms,
title = {{Mechanisms of resistance to immune checkpoint inhibitors in renal cell carcinoma and novel treatment strategies}},
author = {Li Chen and Jie Cheng and Shilong Mao},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1984645},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1984645/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mechanisms of resistance to immune checkpoint inhibitors in renal cell carcinoma and novel treatment strategies
AU - Li Chen
AU - Jie Cheng
AU - Shilong Mao
PY - 2026
DA - 2026/10/19
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1984645
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1984645/full
AB - In recent years, immune checkpoint inhibitors (ICIs), such as nivolumab, ipilimumab, pembrolizumab, and atezolizumab have substantially improved the prognosis of patients with advanced renal cell carcinoma. These agents have greatly changed the management of advanced renal cell carcinoma, shifting the treatment paradigm from cytokine and vascular endothelial growth factor-based therapies to immunotherapy strategies. However, drug resistance limits the long-term benefit. The mechanisms of immunotherapy resistance in RCC are complex. Recently, increasing research has focused on how cancer cells evade the surveillance and attack of the immune system and identifying the molecular and cellular drivers of resistance. In response, combination regimens incorporating ICIs are being developed to alleviate drug resistance and attack cancer cells through multiple pathways. At the same time, novel targeted strategies are under investigation to develop innovative approaches to delay, partially overcome, or bypass resistance in defined clinical settings. This review outlines the mechanisms of immunotherapy resistance in RCC from three interrelated perspectives: cancer cell-intrinsic mechanisms, the tumor microenvironment, and host related factors. We also summarize current efforts to overcome resistance, including ICI combined with tyrosine kinase inhibitors, dual ICI therapy, tumor microenvironment-targeting strategies, radiotherapy combined with immunotherapy, and gut microbiota modulation. Although these new strategies have shown different therapeutic effects in clinical trials, deeper understanding of immune regulation highlights their potential. Moreover, the integration of multi-omics analysis, and microbiome regulation may increase patient choices and optimize therapeutic outcomes, but their clinical efficacy has not been fully confirmed and requires prospective, treatment defined validation. Overall, ICIs have substantially changed RCC treatment, future progress will depend on deeper biological insights, rational combination design, and validated personalized immunotherapy.
SN - 2234-943X
ER -